ERBB2 and breast carcinoma: There are a number of recycling inhibitors available, and we have recently reported that small molecule endosomal recycling inhibitors (ERIs) synergise with HER2-targeting therapies in drug-sensitive and drug-resistant breast cancer cells [12].